Table 1.

Characteristics of patients undergoing salvage surgery after targeted therapy

Case	Gender	Age	Histology	Clinical stage	Metastasis	Driver gene	Targeted therapy agent	Duration of targeted therapy	Other treatment	Therapeutic effect
1	Female	63	Ad	cT2N0M1a, IVa	Pleura effusion	EGFR, exon 19 deletion	Icotinib	46 months	None	PR
2	Male	51	Ad	cT2N3M0, IIIb	LNs	EGFR, exon 21 L858R	Gefitinib	12 months	six cycles of chemotherapy	PR
3	Male	45	Ad	cT2N0M1a, IVa	Pleura effusion	EGFR, exon 19 deletion	Gefitinib	six months	None	PR
4	Female	65	Ad	cT2N0M1b, IVb	lung	EGFR, exon 21 L858R mutation	Icotinib	six months	None	PR
5	Male	40	Ad	cT2bN3M1, IVb	LNs, lung	EGFR, exon 19 deletion	Icotinib	14 months	None	PR
6	Male	42	Ad	cT2N2M0, IIIa	LNs	EGFR, exon 21 L858R mutation	Tarceva	two months	None	SD
7	Male	57	Ad	cT2N2M0, IIIa	LNs	EGFR, exon 21 L861 mutation	Icotinib	three months	None	SD
8	Female	56	Ad	cT2N2M1a, IVa	LNs, pleura effusion	ALK translocation	Crizotinib	eight months	None	PR
9	Female	59	Ad	cT2N2M1b, IVb	LNs, brain	EGFR, exon 19 deletion	Icotinib	two months	Gamma knife for brain metastasis	SD

Ad, adenocarcinoma; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; LNs, lymph nodes; PR, partial response; SD, stable disease.